USA flag logo/image

An Official Website of the United States Government

INDENTIFICATION OF MALE CONTRACEPTIVE LEAD COMPOUNDS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
60695
Program Year/Program:
2002 / SBIR
Agency Tracking Number:
HD042342
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
COMPLEGEN, INC.
1124 COLUMBIA ST, STE 662 SEATTLE, WA 98104-2050
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2002
Title: INDENTIFICATION OF MALE CONTRACEPTIVE LEAD COMPOUNDS
Agency: HHS
Contract: 1R43HD042342-01
Award Amount: $98,808.00
 

Abstract:

DESCRIPTION: (provided by applicant) The long-term objective of this project is to identify lead compounds for the development of male contraceptive drugs. The project takes advantage of: 1) the observation that blocking meiotic recombination in spermatogenesis leads to apoptosis of the developing spermatocytes, and therefore sterility, 2) the high degree of homology of yeast and mammalian meiotic recombination proteins, 3) the observation that many mammalian genes involved in basic cellular functions can functionally substitute for the cognate yeast genes, and 4) the development of simple methods for replacement of yeast with mammalian genes, and 5) the development of simple methods for high throughput screening for interactions between small compounds and specific mammalians genes that are performing essential functions in yeast. In this Phase I applications we propose to replace five genes of yeast that are required for meiotic recombination with their human homologs. Identification of human meiotic recombination genes that can functionally replace the yeast homologs will provide a platform for a Phase II grant. In Phase II, we would perform high throughput screening to identify compounds that block function of the human meiotic genes. These compounds would be candidate male contraceptives, potentially capable of reversibly blocking spermatogenesis. PROPOSED COMMERCIAL APPLICATION: Years of research have failed to produce a male contraceptive drug. Most efforts have focused on hormone-based approaches. This project is designed to identify familes of compounds that should block spermatogenesis in ways less prone to the side effects that have thwarted the development of effective male contraceptives. One third of couples currently use male-based contraceptive approaches. Market research suggests there is broad interest in a male contraceptive drug.

Principal Investigator:

John T. Swindle
2064478076
JSWINDLE@COMPLEGEN.COM

Business Contact:

Joel Hedgpeth
2064478076
CPREMO@COMPLEGEN.COM
Small Business Information at Submission:

COMPLEGEN, INC.
COMPLEGEN, INC. 1124 COLUMBIA ST, STE 662 SEATTLE, WA 98104

EIN/Tax ID: 943343600
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No